10
Participants
Start Date
October 24, 2023
Primary Completion Date
September 30, 2024
Study Completion Date
October 31, 2024
DaxibotulinumtoxinA
"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
The Los Angeles Headache Center, Los Angeles
New England Institute For Clinical Research, Stamford
The Los Angeles Headache Center
UNKNOWN
Revance Therapeutics, Inc.
INDUSTRY
Ki Health Partners. LLC
INDUSTRY